eyeDNA Therapeutics to Present 2-year Follow-up Phase I/II Data on its Investigational Gene Therapy HORA-PDE6b for Retinitis Pigmentosa at the ARVO 2024 Annual Meeting
GlobeNewswire
*Paris, France, April 25, 2024 *– eyeDNA Therapeutics (‘eyeDNA’), a newly created subsidiary of Coave Therapeutics..